Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease

Objective: To investigate whether dopamine D2 and D3 receptor subtypes (D2/3Rs) outside the caudate-putamen are affected in PD. Background: Alterations in striatal D2-like dopamine receptors in PD have been extensively demonstrated using PET, but there are no studies focusing on extrastriatal D2/3Rs. Methods: Fourteen unmedicated patients with idiopathic early PD with predominantly left-sided symptoms, 14 levodopa-medicated patients with advanced PD, and 20 normal age-matched controls were examined using PET. PET scanning was performed with a novel high-affinity D2/3R radioligand ([11C]FLB 457) and a PET scanner in three-dimensional mode. Results: In advanced PD, the binding potential of [11C]FLB 457 in the dorsolateral prefrontal cortex was decreased by 40% (p < 0.01), in the anterior cingulate cortex by 20% (p < 0.01), and in the medial thalamus by 17% (p < 0.05) compared with healthy controls. In early PD, the extrastriatal [11C]FLB 457 binding potentials were not significantly different compared with the control group. However, the binding potential in the anterior cingulate cortex (29%; p < 0.05) was higher in early PD compared with advanced PD. Conclusions: These results imply that the D2/3 receptor subtypes outside the striatum are affected in advanced PD but not in the early stages of the disease, and that this receptor decline is present in the anterior cingulate cortex, the dorsolateral prefrontal cortex, and the thalamus.

[1]  R. C. Oldfield The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.

[2]  J. Fields,et al.  Neurotransmitter receptor alterations in Parkinson's disease. , 1977, Life sciences.

[3]  R. Bannister,et al.  Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease , 1979, Journal of the Neurological Sciences.

[4]  Y Agid,et al.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.

[5]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.

[6]  Bernard J. Ransil,et al.  Associations of handedness with hair color and learning disabilities , 1987, Neuropsychologia.

[7]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[8]  Y. Agid,et al.  D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy , 1988, Journal of the Neurological Sciences.

[9]  D. Weinberger,et al.  Mesocortical Dopaminergic Function and Human Cognition , 1988, Annals of the New York Academy of Sciences.

[10]  J. Palacios,et al.  Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology , 1989, Brain Research.

[11]  C. Pelizzari,et al.  Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.

[12]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[13]  J. Rinne,et al.  Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[14]  K. Någren,et al.  PET demonstrates different behaviour of striatal dopamine D‐1 and D‐2 receptors in early Parkinson's disease , 1990, Journal of neuroscience research.

[15]  V J Cunningham,et al.  Compartmental Analysis of Diprenorphine Binding to Opiate Receptors in the Rat in vivo and its Comparison with Equilibrium Data in vitro , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  Päivi Marjamäki,et al.  A post-mortem study on striatal dopamine receptors in Parkinson's disease , 1991, Brain Research.

[17]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[18]  M. Reivich,et al.  Attention and sentence processing deficits in Parkinson's disease: the role of anterior cingulate cortex. , 1992, Cerebral cortex.

[19]  D. Jewett,et al.  A simple synthesis of [11C]methyl triflate. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[20]  R. Myers,et al.  Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.

[21]  C D Marsden,et al.  Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study , 1993, Synapse.

[22]  R S Frackowiak,et al.  Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.

[23]  U Ruotsalainen,et al.  PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[24]  Robert M. Kessler,et al.  Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride , 1993, Brain Research.

[25]  A. Antonini,et al.  [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.

[26]  R. Dolan,et al.  Depression in Parkinson's disease. A positron emission study. , 1994, The British journal of psychiatry : the journal of mental science.

[27]  S. Dollfus,et al.  A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia , 1994, Biological Psychiatry.

[28]  R. Coppola,et al.  Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Ulla Ruotsalainen,et al.  Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride , 1995, Journal of the Neurological Sciences.

[30]  Thomas K. Lewellen,et al.  Investigation of the performance of the General Electric Advance positron emission tomograph in 3D mode , 1995 .

[31]  T Suhara,et al.  Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  K. Någren,et al.  PET examination of the monoamine transporter with [11c]β‐CIT and [11c]β‐CFT in early parkinson's disease , 1995 .

[33]  T. Di Paolo,et al.  Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. , 1996, Molecular pharmacology.

[34]  Y. Agid,et al.  Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. , 1996, Brain research. Molecular brain research.

[35]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  T. Yanagihara,et al.  Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease , 1996, Neurology.

[37]  D. J. Brooks,et al.  In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias , 1997, Neurology.

[38]  F. Amenta,et al.  Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives. , 1997, Hypertension.

[39]  P. Sokoloff,et al.  Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Christer Halldin,et al.  A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.

[41]  J. Joyce,et al.  Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. , 1997, Journal of psychiatric research.

[42]  J. Petter Gustavsson,et al.  D2 dopamine receptors and personality traits , 1997, Nature.

[43]  F. Tamaru Disturbances in higher function in Parkinson's disease. , 1997, European neurology.

[44]  J. Joyce,et al.  Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[45]  Christer Halldin,et al.  Methylation of amide and thiol functions with [11C]methyl triflate, as exemplified by [11C]NMSP[11C]flumazenil and [11C]methionine , 1998 .

[46]  Victor W. Pike,et al.  Improved syntheses of the PET radioligands, [11C]FLB 457, [11C]MDL 100907 and [11C]β‐CIT‐FE, by the use of [11C]methyl triflate , 1998 .

[47]  A. Markham,et al.  Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. , 1998, Drugs & aging.

[48]  C. Halldin,et al.  Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  J. Joyce,et al.  Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.

[50]  A. Bonnet [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.